Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
Open accessThe DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index; 23 of the 57 sources its claims cite were checked for support.
Abstract
Systematic review of 10 RCTs (14,550 participants) assessing thyroid cancer risk and adverse events of semaglutide. Thyroid cancer incidence less than 1%, suggesting no significant risk. GI symptoms predominant: nausea (2.05-19.95%), diarrhea (1.4-13%).
Overview
CoChat Summary
TL;DR
This systematic review pooled 10 randomized controlled trials of semaglutide involving 14,550 participants and found thyroid cancer incidence to be very low, with reported cases each under 1% in the relevant study groups. The main adverse events were gastrointestinal, especially nausea and diarrhea, while the review found no significant evidence of a thyroid carcinogenic signal for semaglutide.
Key findings
- The final analysis included 10 RCTs published from 2016 to 2022, with 14,550 patients total and 7,830 receiving semaglutide.
- Across the included studies, thyroid cancer incidence was less than 1%, with only isolated cases of papillary thyroid cancer and medullary thyroid cancer reported.
- Reported adverse events were mainly gastrointestinal: nausea ranged from 2.05% to 19.95%, diarrhea from 1.4% to 13%, and average prevalences included nasopharyngitis 8.23%, vomiting 5.97%, headaches 7.92%, constipation 6.91%, and dyspepsia 5.18%.
- Serious adverse events ranged from 7% to 25.2%; among semaglutide-treated patients across 29 studies, there were 320 severe hypoglycemia cases (3.47%), 18 AKI cases (0.20%), and 22 pancreatitis cases (0.24%).
Methods
- Systematic review following PRISMA; searches were conducted in PubMed, Scopus, and Embase up to December 2023, using semaglutide/thyroid cancer/safety-related terms.
- Included human, peer-reviewed English studies on semaglutide in patients with diabetes and/or obesity that reported thyroid cancer incidence and/or adverse events; excluded non-human, grey literature, and studies without relevant outcomes.
- Quality/risk of bias for observational studies was assessed with the Newcastle–Ottawa Scale; screening and quality assessment were done independently by two reviewers with a third reviewer for disagreements.
Limitations
- The paper states that post-marketing and real-world use were not covered, so delayed adverse outcomes could not be assessed.
- The studies were highly variable, making a funnel plot analysis for publication bias impossible and the outcome reporting too non-uniform to conduct a meta-analysis effectively.
- Evident from the text: the synthesis relied on RCTs and selected reported outcomes, so very rare events and longer-term risks may be underpowered or incompletely captured.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
11 Valid · 4 Not valid · 15 Not checked · 26 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Serious adverse events varied from 7% to 25.2%”
- Also stated in: § 3.4. Thyroid Cancer Incidence and Complications · plain
“Major side complications were predominantly serious adverse events, with rates varying from 7% to 25.2% [26,29].”
§ Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review > Abstract The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. This systematic review aims to assess the incidence of thyroid cancer and detail the spectrum of adverse events associated with semaglutide, focusing on its implications for patient care. Through a systematic search of PubMed, Scopus, and Embase databases up to December 2023, ten randomized controlled trials (RCTs) involving 14,550 participants, with 7830 receiving semaglutide, were analyzed, with an additional number of 18 studies that were separately discussed because they reported data from the same RCTs. The review focused on thyroid cancer incidence, gastrointestinal symptoms, and other significant adverse events attributed to semaglutide. The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. Adverse events were predominantly gastrointestinal, including nausea (2.05% to 19.95%) and diarrhea (1.4% to 13%). Nasopharyngitis and vomiting were also notable, with mean prevalences of 8.23% and 5.97%, respectively. Other adverse events included increased lipase levels (mean of 6.5%), headaches (mean prevalence of 7.92%), decreased appetite (reported consistently at 7%), influenza symptoms (mean prevalence of 5.23%), dyspepsia (mean prevalence of 5.18%), and constipation (mean prevalence of 6.91%). Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. These findings underscore the gastrointestinal nature of semaglutide’s adverse events, which, while prevalent, did not significantly deter from its clinical benefits in the treatment landscape. This systematic review provides a comprehensive assessment of semaglutide’s safety profile, with a focus on gastrointestinal adverse events and a low incidence of thyroid cancer. Despite the prevalence of gastrointestinal symptoms, semaglutide remains an efficacious option for managing diabetes and obesity. The detailed characterization of adverse events underscores the importance of monitoring and managing these effects in clinical practice, excluding the hypothesis of carcinogenesis.
What the sources say
- Disputedcites [26] Marso, 2016, Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The adverse-event table reproduced in the Discussion reports serious adverse events in 33.6% to 39.9% of this trial’s groups, not 7% to 25.2%. Its 25.2% figure refers to severe adverse events, a separately defined category; the paper does not report a range across studies. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [29] Sorli, 2017, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial, Lancet Diabetes Endocrinol. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.4. Thyroid Cancer Incidence and Complications · plain
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“this group experienced a lower incidence of acute kidney injury (AKI) and pancreatitis, with only three cases (0.20%) and one case (0.07%), respectively.”
§ Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review > 4. Discussion > 4.1. Summary of Evidence
What the sources say
- Not checked — no full text of the sourcecites [23] Masmiquel, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial, Lancet Diabetes Endocrinol. source
- Not checked — no full text of the sourcecites [28] Rosenstock, 2019, Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled with Metformin Alone or with Sulfonylurea: The PIONEER 3 Randomized Clinical Trial, JAMA source
- Disputedcites [48] Ji, 2021, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial, Diabetes Obes. Metab. sourceExperimental — accuracy not yet measured
The Results (Participant disposition and baseline characteristics) state that the sitagliptin group had 290 patients. Three cases among 290 patients would be about 1.03%, not 0.20%, so the claimed percentage is incompatible with this trial's group size. The passages found do not report an acute kidney injury count. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“this group experienced a lower incidence of acute kidney injury (AKI) and pancreatitis, with only three cases (0.20%) and one case (0.07%), respectively.”
§ Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review > 4. Discussion > 4.1. Summary of Evidence
What the sources say
- Not checked — no full text of the sourcecites [23] Masmiquel, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial, Lancet Diabetes Endocrinol. source
- Not checked — no full text of the sourcecites [28] Rosenstock, 2019, Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled with Metformin Alone or with Sulfonylurea: The PIONEER 3 Randomized Clinical Trial, JAMA source
- Disputedcites [48] Ji, 2021, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial, Diabetes Obes. Metab. sourceExperimental — accuracy not yet measured
The Results (Safety and tolerability, Table 3) report zero EAC-confirmed mild acute pancreatitis cases in the sitagliptin group. The single case occurred in the semaglutide 1.0 mg group, where it represented 0.3%, not 0.07%. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The sitagliptin group comprised 1518 patients, within which there were 62 reported cases of severe hypoglycemia, resulting in a proportion of approximately 4.08%.”
§ Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review > 4. Discussion > 4.1. Summary of Evidence
What the sources say
- Not checked — no full text of the sourcecites [23] Masmiquel, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial, Lancet Diabetes Endocrinol. source
- Not checked — no full text of the sourcecites [28] Rosenstock, 2019, Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled with Metformin Alone or with Sulfonylurea: The PIONEER 3 Randomized Clinical Trial, JAMA source
- Disputedcites [48] Ji, 2021, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial, Diabetes Obes. Metab. sourceExperimental — accuracy not yet measured
The Results (Participant disposition and baseline characteristics) report 290 patients in the sitagliptin group, not 1,518. The Results (Safety and tolerability) explicitly state that no severe hypoglycaemia episodes were reported; Table 3 lists four sitagliptin patients (1.4%) with severe or blood-glucose-confirmed hypoglycaemia, a broader category than severe hypoglycaemia alone. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plainn = 62- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk.”
- Also stated in: § 3.4. Thyroid Cancer Incidence and Complications · plain
“Across the 10 studies, thyroid cancer incidence was notably low, with a few isolated cases of papillary thyroid cancer and medullary thyroid cancer reported, each constituting less than 1% within the respective study groups [23,25,30,32]”
- Also stated in: § 4.1. Summary of Evidence · plain
“the incidence of thyroid cancer was remarkably low, with reported cases being isolated and representing less than 1% of study populations.”
§ Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review > Abstract The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. This systematic review aims to assess the incidence of thyroid cancer and detail the spectrum of adverse events associated with semaglutide, focusing on its implications for patient care. Through a systematic search of PubMed, Scopus, and Embase databases up to December 2023, ten randomized controlled trials (RCTs) involving 14,550 participants, with 7830 receiving semaglutide, were analyzed, with an additional number of 18 studies that were separately discussed because they reported data from the same RCTs. The review focused on thyroid cancer incidence, gastrointestinal symptoms, and other significant adverse events attributed to semaglutide. The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. Adverse events were predominantly gastrointestinal, including nausea (2.05% to 19.95%) and diarrhea (1.4% to 13%). Nasopharyngitis and vomiting were also notable, with mean prevalences of 8.23% and 5.97%, respectively. Other adverse events included increased lipase levels (mean of 6.5%), headaches (mean prevalence of 7.92%), decreased appetite (reported consistently at 7%), influenza symptoms (mean prevalence of 5.23%), dyspepsia (mean prevalence of 5.18%), and constipation (mean prevalence of 6.91%). Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. These findings underscore the gastrointestinal nature of semaglutide’s adverse events, which, while prevalent, did not significantly deter from its clinical benefits in the treatment landscape. This systematic review provides a comprehensive assessment of semaglutide’s safety profile, with a focus on gastrointestinal adverse events and a low incidence of thyroid cancer. Despite the prevalence of gastrointestinal symptoms, semaglutide remains an efficacious option for managing diabetes and obesity. The detailed characterization of adverse events underscores the importance of monitoring and managing these effects in clinical practice, excluding the hypothesis of carcinogenesis.
What the sources say
- Not checked — no full text of the sourcecites [23] Masmiquel, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial, Lancet Diabetes Endocrinol. source
- Partly supportedcites [25] Husain, 2019, Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Adverse Events and Safety section reports one medullary thyroid cancer case among 1,591 oral semaglutide recipients, an incidence below 1%. This paper reports one trial, not 10 included RCTs, and does not establish that thyroid-cancer risk was not significant. (LLM, conf=0.88)
- Partly supportedcites [30] Wadden, 2021, Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
The Adverse Events section reports one papillary thyroid cancer among 407 semaglutide-treated participants, consistent with an incidence below 1% in this trial. This paper reports a single RCT, not the 10 included RCTs, and does not establish that semaglutide poses no significant thyroid-cancer risk. Page numbers were not available in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [32] Yamada, 2020, PIONEER 9 investigators. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): A 52-week, phase 2/3a, randomised, controlled trial, Lancet Diabetes Endocrinol. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § 3.4. Thyroid Cancer Incidence and Complications · plain
29 more claims · 6 with their cited sources checked
Create a free account to see all 56 claims and to verify the 2 references still open.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 11
Citations
Cites
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396 · cited 2×
“O tt awa Scale [22].”
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · cited 1×
“Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [21], this systematic review protocol ensures a structured, transparent, and reproducible methodology.”
MethodSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 5×
“Adverse events commonly reported were gastrointestinal in nature, such as nausea and diarrhea, with occurrences ranging from 2.05% to 19.95% for nausea [24,26] and 1.4% to 13% for diarrhea [23,29].”
InfluentialTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 6×
“…studies were excluded from the final analysis due to a lack of mention of cancer incidence or thyroid cancer incidence in their study population, their focus on studying outcomes from the same clinical trials, or their lack of focus on patients with diabetes mellitus and obesity [25,33–49].”
BackgroundMethodResultInfluentialRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“Similarly, trials such as Davies M et al. [36], Loomba R et al. [37], and Weghuber D et al. [41] did not center on diabetes or obesity as primary conditions, thereby not meeting the inclusion criteria, which focused on these specific chronic diseases.”
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 4×
“The analysis uncovered an average age of approximately 57.3 years among the participants, while the ages of participants across these studies ranged from an average of 46 years in the studies by Wadden et al. [30] and Wilding et al. [31] to 66 years in Husain et al. [25].”
InfluentialWadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 6×
“…accompanied by notable weight loss, with changes from − 1.9 kg in the study by Ahr é n et al. [23] with Sitagliptin as the comparison group, to an impressive − 16.0% of body weight loss reported in Wadden et al. [30] with a 2.4 mg weekly dose of subcutaneous semaglutide, as presented in Table 3.”
BackgroundMethodResultInfluentialTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · cited 1×
“…severe complications revealed that a total of 9228 patients took semaglutide across 29 studies [ 23– 50 In a detailed examination of studies involving patients treated with sitagliptin [23,28,48] and liraglutide [27,43,46] as comparison groups for semaglutide, distinct outcomes have been observed.”
BackgroundSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 10×
“Follow-up durations extended from 30 weeks in Sorli et al. [29] to an integrated period of 120 weeks in Wilding et al. [31], providing a comprehensive view of semaglutide’s long-term efficacy and safety.”
InfluentialOnce-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“Recent rodent studies indicate that long-term exposure to liraglutide, a GLP-1 receptor agonist, can lead to thyroid C-cell hyperplasia and tumors due to a GLP-1 receptor-mediated mechanism in rodents, which contrasts with the lack of similar findings in primates [17].”
ResultPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · cited 2×
“…severe complications revealed that a total of 9228 patients took semaglutide across 29 studies [ 23– 50 In a detailed examination of studies involving patients treated with sitagliptin [23,28,48] and liraglutide [27,43,46] as comparison groups for semaglutide, distinct outcomes have been observed.”
BackgroundLoomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533 · cited 1×
“Similarly, trials such as Davies M et al. [36], Loomba R et al. [37], and Weghuber D et al. [41] did not center on diabetes or obesity as primary conditions, thereby not meeting the inclusion criteria, which focused on these specific chronic diseases.”
ResultAhrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495 · cited 9×
“Severe hypoglycemia and pancreatitis were reported as well, albeit less commonly [23].”
BackgroundMethodResultInfluentialAroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493 · cited 3×
“For instance, studies such as those by Aroda VR et al. [33] and Zinman B et al. [35] were omitted because they did not focus on or mention thyroid cancer incidence, despite discussing semaglutide’s effects in diabetes management.”
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421 · cited 2×
“…severe complications revealed that a total of 9228 patients took semaglutide across 29 studies [ 23– 50 In a detailed examination of studies involving patients treated with sitagliptin [23,28,48] and liraglutide [27,43,46] as comparison groups for semaglutide, distinct outcomes have been observed.”
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412 · cited 1×
“…severe complications revealed that a total of 9228 patients took semaglutide across 29 studies [ 23– 50 In a detailed examination of studies involving patients treated with sitagliptin [23,28,48] and liraglutide [27,43,46] as comparison groups for semaglutide, distinct outcomes have been observed.”
BackgroundMosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351 · cited 1×
“The PIONEER trial series, such as PIONEER 1 by Aroda VR et al. [33] and PIONEER 5 by Mosenzon O et al. [34], were omitted because they either reported on the same patient groups as the included studies without mentioning thyroid cancer incidence or investigated patient subgroups outside this…”
MethodSmits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · cited 1×
“The Food and Drug Administration (FDA) has issued a boxed warning for semaglutide, based on animal studies indicating a risk for thyroid C-cell tumors [16].”
BackgroundKadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320 · cited 1×
“[52] on the risk of thyroid cancer associated with GLP-1 receptor agonists diverges from our findings regarding semaglutide, suggesting a potential increased risk for thyroid cancer.”
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care · doi:10.2337/dc19-0898 · Cited by 300 · cited 1×
“For instance, studies such as those by Aroda VR et al. [33] and Zinman B et al. [35] were omitted because they did not focus on or mention thyroid cancer incidence, despite discussing semaglutide’s effects in diabetes management.”
BackgroundLingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245 · cited 1×
“Semaglutide operates by enhancing insulin secretion and suppressing glucagon release, which in turn helps control blood sugar levels and supports weight loss [7,8].”
Adiposity and risk of thyroid cancer: A systematic review and meta-analysis
Schmid, D., Ricci, C., Behrens, G., & Leitzmann, M. F. (2015) · Obesity Reviews · doi:10.1111/obr.12321 · Cited by 244 · cited 1×
“Schmid et al. [53] uncovered that obesity is linked to a significantly higher risk of thyroid cancer, with over-weight individuals facing a 25% increased risk and obese individuals a 55% increased risk compared to their normal-weight counterparts.”
BackgroundYamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30075-9 · Cited by 228 · cited 5×
“Significant reductions in HbA1c were reported, ranging from − 0.2% in the study by Buse et al. [24] with a flexible dose of oral semaglutide, to − 1.7% for the 14 mg dose in the study by Yamada et al. [32], demonstrating semaglutide’s robust glycemic control capabilities across various dosages.”
BackgroundInfluentialMahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166 · cited 2×
“The drug has demonstrated significant utility in managing type 2 diabetes and obesity, thanks to its action as a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) [4–6].”
BackgroundShu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
Kaku, K., Yamada, Y., Watada, H., Abiko, A., Nishida, T., Zacho, J., & Kiyosue, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13218 · Cited by 132 · cited 1×
“…studies were excluded from the final analysis due to a lack of mention of cancer incidence or thyroid cancer incidence in their study population, their focus on studying outcomes from the same clinical trials, or their lack of focus on patients with diabetes mellitus and obesity [25,33–49].”
BackgroundHu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127 · cited 1×
“Conversely, Hu et al.’s investigation into GLP-1RAs presented a nuanced picture, indicating an association between GLP-1RA use and an increased risk of general thyroid disorders (RR 1.28, 95% CI 1.03–1.60), but not specifically thyroid cancer (RR 1.30, 95% CI 0.86–1.97) [54].”
InfluentialMinireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122 · cited 1×
“…study found that administering a dose of liraglutide eight times higher than the highest approved dose for humans was associated with a potential carcinogenic factor, indicating that GLP-1RAs may have a dose-dependent effect on cell proliferation in thyroid dysplastic or premalignant lesions [55].”
BackgroundYang, Z., Lv, Y., Yu, M., Mei, M., Xiang, L., Zhao, S., & Li, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925377 · Cited by 120 · cited 1×
“However, the rise in GLP1-RAs use has necessitated a thorough evaluation of its safety profile, particularly concerning its carcinogenic potential [15].”
BackgroundSilverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Ji, L., Dong, X., Li, Y., Li, Y., Lim, S., Liu, M., Ning, Z., Rasmussen, S., Skjøth, T. V., Yuan, G., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14232 · Cited by 113 · cited 2×
“…severe complications revealed that a total of 9228 patients took semaglutide across 29 studies [ 23– 50 In a detailed examination of studies involving patients treated with sitagliptin [23,28,48] and liraglutide [27,43,46] as comparison groups for semaglutide, distinct outcomes have been observed.”
BackgroundResultMahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03302-1 · Cited by 110 · cited 1×
“Semaglutide operates by enhancing insulin secretion and suppressing glucagon release, which in turn helps control blood sugar levels and supports weight loss [7,8].”
Overgaard, R. V., Hertz, C. L., Ingwersen, S. H., Navarria, A., & Drucker, D. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100387 · Cited by 99 · cited 1×
“%) were for the injection form at a concentration of 2 mg per 1.5 mL, showcasing its preferred method of administration for its efficacy in glycemic control and weight management [9,10].”
MethodInfluentialKellerer, M., Kaltoft, M. S., Lawson, J., Nielsen, L. L., Strojek, K., Tabak, Ö., & Jacob, S. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14765 · Cited by 86 · cited 2×
“Similarly, the SUSTAIN and STEP series, including trials such as SUSTAIN 11 by Kellerer M et al. [47] and STEP TEENS by Weghuber D et al. [41], were not considered, as they either overlapped with included studies or did not report on this review’s primary outcomes.”
MethodResultSemaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86 · cited 2×
“Regarding the risk of other cancer types, the study by Nagendra et al. [50] did not identify any significant risk in any types of neoplasms associated with semaglutide use, with an overall odds ratio of 0.95 (95% CI: 0.62–1.45).”
InfluentialChao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58 · cited 1×
“Semaglutide was approved for medical use in the US in 2017, and its indications have expanded over the years to include not just type 2 diabetes management but also long-term weight management for adults with obesity or who are overweight and have at least one weight-related comorbidity [20].”
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts
Thompson, C. A., & Stürmer, T. (2023) · Diabetes Care · doi:10.2337/dci22-0052 · Cited by 51 · cited 1×
“…these findings raise concerns, the direct applicability to human risk remains uncertain, underscoring the importance of conducting additional studies to assess the carcinogenic effect, especially the thyroid carcinogenic risk associated with semaglutide, given the in vitro study findings [18,19].”
O’Neill, E. S., Wiegmann, A. L., Parrella, N., Pittman, T., Hood, K., & Kurlander, D. (2024) · Plastic and Reconstructive Surgery - Global Open · doi:10.1097/gox.0000000000005516 · Cited by 43 · cited 2×
“In 2021, Ozempic (semaglutide) was one of the most prescribed medications in the United States [1], with over 9 million prescriptions in the final quarter of 2022 [2], with the possibility of reaching as much as 24 million prescriptions by 2035 in the USA alone [3].”
BackgroundBuse, J. B., Bode, B. W., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Nielsen, M. A., & Pieber, T. R. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001649 · Cited by 38 · cited 8×
“Significant reductions in HbA1c were reported, ranging from − 0.2% in the study by Buse et al. [24] with a flexible dose of oral semaglutide, to − 1.7% for the 14 mg dose in the study by Yamada et al. [32], demonstrating semaglutide’s robust glycemic control capabilities across various dosages.”
BackgroundMethodInfluentialGlucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Wojtara, M., Mazumder, A., Syeda, Y., & Mozgała, N. (2023) · Advances in Medicine · doi:10.1155/2023/9946924 · Cited by 36
Jianu, C., Rusu, L. C., Muntean, I., Cocan, I., Lukinich-Gruia, A. T., Goleț, I., Horhat, D. I., Mioc, M., Mioc, A., Şoica, C., et al. (2022) · Antioxidants · doi:10.3390/antiox11122472 · Cited by 31 · cited 1×
“Moreover, these effects may be exacerbated when semaglutide is taken in association with other sub-stances [11–14].”
BackgroundLajthia, E., Bucheit, J. D., Nadpara, P. A., Dixon, D. L., Caldas, L. M., Murchie, M., & Sisson, E. M. (2019) · Pharmacy Practice · doi:10.18549/pharmpract.2019.4.1588 · Cited by 25
ENĂTESCU, V. R. (2020) · FARMACIA · doi:10.31925/farmacia.2020.3.14 · Cited by 16
Lombrea, A., Romanescu, M., Jianu, N., Andor, M., Suciu, M., Man, D. E., Danciu, C., Dehelean, C. A., & Buda, V. (2023) · Pharmaceuticals · doi:10.3390/ph16060853 · Cited by 8 · cited 2×
“The drug has demonstrated significant utility in managing type 2 diabetes and obesity, thanks to its action as a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) [4–6].”
Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist
Vemula, H., Villanueva, F. S., Nguyen, H. D., Mohan, A., & Potluri, S. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab048.1823 · Cited by 3 · cited 1×
“…these findings raise concerns, the direct applicability to human risk remains uncertain, underscoring the importance of conducting additional studies to assess the carcinogenic effect, especially the thyroid carcinogenic risk associated with semaglutide, given the in vitro study findings [18,19].”
Research works printed but not linked: 1
- (2024, February 15). Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet], Available online: https://www.ncbi.nlm.nih.gov/books/NBK544016/.
Cited by
Lin, A., Ding, Y., Li, Z., Jiang, A., Liu, Z., Wong, H. Z. H., Cheng, Q., Zhang, J., & Luo, P. (2025) · Biomarker Research · doi:10.1186/s40364-025-00765-3 · Cited by 69
Capuccio, S., Scilletta, S., Rocca, F. L., Miano, N., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Scicali, R., Piro, S., & Pino, A. D. (2024) · Biomolecules · doi:10.3390/biom14060687 · Cited by 48
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Weiskirchen, R., & Lonardo, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70003 · Cited by 30
“(Feier et al., 2024).”
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Janić, M., Škrgat, S., Harlander, M., Lunder, M., Janež, A., Stoian, A. P., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60122030 · Cited by 33
“Furthermore, thyroid cancer has been shown to exhibit an association with overweight and obesity, implying that the population targeted for treatment with these drugs may have an increased predisposition to thyroid cancer development [28].”
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“While direct evidence linking GLP-1 RAs to thyroid cancer remains limited, these precautions emphasize the importance of individual risk assessment before initiating therapy [157].”
Metadata
- Authors
- Feier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C.
- Affiliations
- First Discipline of Surgery, Department X-Surgery, “Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
- Lucian Blaga University of Sibiu (RO)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
- Medical Informatics and Biostatistics, Department III-Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
- Corresponding author
- Vonica, Razvan
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-04-15
- Volume
- 25
- Issue
- 8
- Pages
- 4346
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11050669
- OpenAlex
- W4394821829
- Cited by
- 60
- References
- 54
- Citations by year
- 2026: 18 · 2025: 35 · 2024: 8
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, GLP-1 receptor agonists, thyroid cancer risk, drug safety, adverse events, gastrointestinal adverse effects, nausea, diarrhea
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Diabetes Mellitus, Type 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

